Health
FDA Publishes Ivonescimab Rejection Letter, Revealing 93% of Trial Data Came From China
The FDA's published rejection letter shows 93% of the trial's key events occurred in China — and asks…
The FDA's published rejection letter shows 93% of the trial's key events occurred in China — and asks…